Trial Profile

Solriamfetol for ADHD in Adults: A Double-Blind Placebo Controlled Pilot Study

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 07 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Solriamfetol (Primary)
Indications Attention-deficit hyperactivity disorder
Focus Therapeutic Use

Most Recent Events

09 Oct 2023 Primary endpoint (Adult ADHD Investigator Symptom Rating Scale (AISRS)) has been met according to the results published in the Journal of Clinical Psychiatry.
09 Oct 2023 Results (n =60) assessing effects and tolerability of solriamfetol as a treatment for ADHD in adults published in the Journal of Clinical Psychiatry
21 Mar 2023 Status changed from planning to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com